Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis.

Posted on September 5, 2017 by David

Cover image

“Cannabidiol (CBD) is one of the most important compounds in Cannabis sativa, lacks psychotropic effects, and possesses a high number of therapeutic properties including the amelioration of experimental autoimmune encephalomyelitis (EAE).

The aim of this study was to analyse the relative efficacy of CBD in adoptively transferred EAE (at-EAE), a model that allows better delineation of the effector phase of EAE.

Preventive intraperitoneal treatment with CBD ameliorated the clinical signs of at-EAE. CBD markedly improved the clinical signs of at-EAE and reduced infiltration, demyelination and axonal damage. The CBD-mediated decrease in the viability of encephalitogenic cells involves ROS generation, apoptosis and a decrease in IL-6 production and may contribute to the therapeutic effect of this compound.”

https://www.ncbi.nlm.nih.gov/pubmed/28867485

http://www.sciencedirect.com/science/article/pii/S0014488617302212

Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy.

Posted on April 4, 2017 by David

“The present study reports the behavioral, electrophysiological, and neuropathological effects of cannabidiol (CBD), a major non-psychotropic constituent of Cannabis sativa, in the intrahippocampal pilocarpine-induced status epilepticus (SE) rat model. Our findings demonstrate anticonvulsant and neuroprotective effects of CBD preventive treatment in the intrahippocampal pilocarpine epilepsy model, either as single or multiple administrations, reinforcing the potential role of CBD in the treatment of epileptic disorders.” https://www.ncbi.nlm.nih.gov/pubmed/28367124

“This study showed that CBD treatment reduces the behavioral severity and oscillatory electrographic changes of SE, the post-ictal lethargy, and the neuronal loss associated with the pilocarpine-induced SE rat model. More studies are needed to understand the specific mechanisms of action related to the neuroprotective and anticonvulsant effects of CBD in epilepsy.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355474/

Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia

Posted on February 10, 2016 by David

“Currently, the pharmacotherapy of schizophrenia is still associated with significant side effects and high rates of treatment resistance, causing a great deal of suffering to patients and their caregivers. Developing safe interventions able to prevent the emergence of full-blown psychosis would therefore represent a major advance.

Cannabidiol (CBD) is a non-psychotomimetic compound of Cannabis sativa that presents antipsychotic properties in animal models and humans.

However, despite the growing evidence of CBD’s neuroprotective effects and therapeutic application in schizophrenia, so far no study has addressed its potential as a preventive intervention.”

http://www.schres-journal.com/article/S0920-9964(16)30060-3/abstract

http://www.thctotalhealthcare.com/category/schizophrenia/

CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion.

Posted on June 24, 2015 by David

“Preventive treatment with cannabinoid agonists has been reported to reduce the infarct size in a mouse model of myocardial ischemia/reperfusion.

Here we investigated the possible cardioprotective effect of selective CB(2) cannabinoid receptor activation during ischemia.

Our data suggest that administration during ischemia reduces the infarct size in a mouse model of myocardial ischemia/reperfusion through a direct cardioprotective activity on cardiomyocytes and neutrophils.”

http://www.ncbi.nlm.nih.gov/pubmed/19162037